3 news items
Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update
LQDA
13 May 24
with L606. The sustained-release liposomal formulation of treprostinil is being evaluated in an open-label study in PH-ILD and PAH patients. To date
Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD
LQDA
10 May 24
/publications. About L606 (liposomal treprostinil) inhalation suspension L606 is an investigational, sustained-release
Liquidia Corporation Reports Full Year 2023 Financial Results and Provides Corporate Update
LQDA
13 Mar 24
industry leading portfolio for inhaled treprostinil with YUTREPIA and sustained-release program L606Company to host
- Prev
- 1
- Next